Bible moralisée, texte latin avec la traduction, jusqu'à Isaïe.

Commençant par : « In principio creavit Deus... » Glose : « Creatio lucis angelorum creationem... Au commencement Dieu crea... La creation de lumiere emporte la creation des anges... » et finissant par : «... quia excidisti sepulcrum ». Glose : «... et accederent ad verum sacrificium... car tu as taillé et appareillé ton sepulcre... et venissent au vray sacrifice ».

Partie d'une « Bible historiée toute figurée ».

Miniatures italiennes à chaque page. — Cet exemplaire n'est pas, comme on l'a cru, celui qui avait appartenu à la reine Jeanne d'Évreux, femme de Charles le Bel, puis au roi Charles V.

Divers cartonnages de momie. Egyptien 164

Scarabée poussant le disque solaire ; Nout aux aîles déployées et une scène inspirée du chapitre 89 du Livre des Morts (Isis et Nephtys veille sur le défunt momifié dont s’éloigne le ba) ; représentation de génies funéraires.Une formule funéraire très endommagée.Très similaire à E 165

Idarubicin-loaded beads for chemoembolisation of hepatocellular carcinoma: results of the IDASPHERE phase I trial.

BACKGROUND: A phase I dose-escalation trial of transarterial chemoembolisation (TACE) with idarubicin-loaded beads was performed in cirrhotic patients with hepatocellular carcinoma (HCC). AIM: To estimate the maximum-tolerated dose (MTD) and to assess safety, efficacy, pharmacokinetics and quality of life. METHODS: Patients received a single TACE session with injection of 2 mL drug-eluting beads (DEBs; DC Bead 300-500 μm) loaded with idarubicin. The idarubicin dose was escalated according to a modified continuous reassessment method. MTD was defined as the dose level closest to that causing dose-limiting toxicity (DLT) in 20% of patients. RESULTS: Twenty-one patients were enrolled, including nine patients at 5 mg, six patients at 10 mg, and six patients at 15 mg. One patient at each dose level experienced DLT (acute myocardial infarction, hyperbilirubinaemia and elevated aspartate aminotransferase (AST) at 5-, 10- and 15-mg, respectively). The calculated MTD of idarubicin was 10 mg. The most frequent grade ≥3 adverse events were pain, elevated AST, elevated γ-glutamyltranspeptidase and thrombocytopenia. At 2 months, the objective response rate was 52% (complete response, 28%, and partial response, 24%) by modified Response Evaluation Criteria in Solid Tumours. The median time to progression was 12.1 months (95% CI 7.4 months - not reached); the median overall survival was 24.5 months (95% CI 14.7 months - not reached). Pharmacokinetic analysis demonstrated the ability of DEBs to release idarubicin slowly. CONCLUSIONS: Using drug-eluting beads, the maximum-tolerated dose of idarubicin was 10 mg per TACE session. Encouraging responses and median time to progression were observed. Further clinical investigations are warranted (NCT01040559).

1.° Registrum patrimonii beati Petri in Tuscia, compositum anno 1291. a Raynaldo, Episcopo Senensi. — 2.° Descriptio provinciae patrimonii et civitatis Sabinae

Colbertinus